These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 5322559)

  • 1. A comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. NSAM-945.
    Wood CD; Graybiel A; Kennedy RS
    Res Rep U S Nav Sch Aviat Med; 1965 Jul; ():1-9. PubMed ID: 5322559
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room.
    Wood CD; Graybiel A; Kennedy RS
    Aerosp Med; 1966 Mar; 37(3):259-62. PubMed ID: 5907763
    [No Abstract]   [Full Text] [Related]  

  • 3. EVALUATION OF SOME ANTIMOTION SICKNESS DRUGS ON THE SLOW ROTATION ROOM (NO. 1). NSAM-922.
    WOOD CD; GRAYBIEL A; MCDONOUGH RG; KENNEDY RS
    Res Rep U S Nav Sch Aviat Med; 1965 Mar; 15():1-11. PubMed ID: 14313053
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of drugs in altering susceptibility to motion sickness in aerobatics and the slow rotation room.
    Deane FR; Wood CD; Graybiel A
    Aerosp Med; 1967 Aug; 38(8):842-5. PubMed ID: 6049246
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions.
    Wood CD; Graybiel A
    Aerosp Med; 1968 Dec; 39(12):1341-4. PubMed ID: 4881887
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side effects of some antimotion sickness drugs as measured by psychomotor test and questionnaires.
    Kennedy RE; Wood CD; Graybiel A; McDonough RB
    Aerosp Med; 1966 Apr; 37(4):408-11. PubMed ID: 5954449
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention and treatment of space sickness in shuttle-orbiter missions.
    Graybiel A
    Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human centrifuge studies on the relative effectiveness of some antimotion sickness drugs.
    Wood CD; Graybiel A; McDonough R
    Aerosp Med; 1966 Feb; 37(2):187-90. PubMed ID: 5906041
    [No Abstract]   [Full Text] [Related]  

  • 13. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
    Wood CD; Stewart JJ; Wood MJ; Manno JE; Manno BR; Mims ME
    Aviat Space Environ Med; 1990 Feb; 61(2):157-61. PubMed ID: 2178599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of anti-motion sickness drugs in the squirrel monkey.
    Cheung BS; Money KE; Kohl RL; Kinter LB
    J Clin Pharmacol; 1992 Feb; 32(2):163-75. PubMed ID: 1613127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 17. Human assay of antimotion sickness drugs.
    Graybiel A; Wood CD; Knepton J; Hoche JP; Perkins GF
    Aviat Space Environ Med; 1975 Sep; 46(9):1107-18. PubMed ID: 1100039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new antinauseant drug for the prevention of motion sickness.
    Graybiel A; Knepton J
    Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.